A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,900 shares of CRDF stock, worth $73,612. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,900
Previous 26,500 9.81%
Holding current value
$73,612
Previous $141,000 62.41%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.22 - $5.89 $123,867 - $328,638
55,796 New
55,796 $123,000
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.55 $26,649 - $43,028
27,760 New
27,760 $41,000
Q2 2023

Aug 14, 2023

BUY
$1.37 - $1.95 $108,388 - $154,276
79,116 Added 1129.1%
86,123 $126,000
Q1 2023

May 15, 2023

BUY
$1.45 - $2.09 $1,871 - $2,698
1,291 Added 22.59%
7,007 $11,000
Q4 2022

Feb 14, 2023

SELL
$1.22 - $1.66 $237,343 - $322,943
-194,544 Reduced 97.15%
5,716 $8,000
Q3 2022

Nov 14, 2022

BUY
$1.54 - $3.21 $108,975 - $227,149
70,763 Added 54.64%
200,260 $308,000
Q2 2022

Aug 15, 2022

SELL
$1.17 - $2.61 $553,386 - $1.23 Million
-472,980 Reduced 78.51%
129,497 $285,000
Q1 2022

May 16, 2022

BUY
$2.11 - $7.25 $924,926 - $3.18 Million
438,354 Added 267.09%
602,477 $1.49 Million
Q4 2021

Feb 14, 2022

SELL
$5.18 - $7.24 $3.69 Million - $5.16 Million
-712,525 Reduced 81.28%
164,123 $986,000
Q3 2021

Nov 15, 2021

SELL
$5.01 - $7.58 $1.54 Million - $2.33 Million
-306,902 Reduced 25.93%
876,648 $5.84 Million
Q2 2021

Aug 16, 2021

SELL
$6.65 - $10.04 $768,181 - $1.16 Million
-115,516 Reduced 8.89%
1,183,550 $7.87 Million
Q1 2021

May 17, 2021

BUY
$9.1 - $19.57 $3.93 Million - $8.46 Million
432,101 Added 49.84%
1,299,066 $12 Million
Q4 2020

Feb 16, 2021

BUY
$12.02 - $24.71 $8.54 Million - $17.6 Million
710,854 Added 455.35%
866,965 $15.6 Million
Q3 2020

Nov 16, 2020

BUY
$4.25 - $14.19 $663,471 - $2.22 Million
156,111 New
156,111 $2.22 Million

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $133M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.